Key Points
- CEO Peter Blume-Jensen sold 14,036 Acrivon Therapeutics shares at an average price of $2.21, generating $31,019.56. The sale covered tax-withholding obligations, and he retained 2.23 million shares afterward.
- Acrivon shares opened at $2.15, with a market capitalization of approximately $92.1 million. The company reported a quarterly loss of $0.43 per share, beating analyst expectations of a $0.50 loss.
- Institutional investors own 71.62% of the company, while analysts maintain a consensus “Moderate Buy” rating and a $13.50 price target, despite one recent downgrade to “sell.”
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CEO Peter Blume-Jensen sold 14,036 shares of the company's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total value of $31,019.56. Following the transaction, the chief executive officer directly owned 2,230,052 shares in the company, valued at $4,928,414.92. This represents a 0.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Peter Blume-Jensen also recently made the following trade(s):
- On Tuesday, August 18th, Peter Blume-Jensen sold 484 shares of Acrivon Therapeutics stock. The stock was sold at an average price of $2.01, for a total value of $972.84.
- On Tuesday, August 18th, Peter Blume-Jensen sold 1,229 shares of Acrivon Therapeutics stock. The shares were sold at an average price of $2.01, for a total value of $2,470.29.
Acrivon Therapeutics Stock Performance
Shares of NASDAQ ACRV opened at $2.15 on Friday. Acrivon Therapeutics, Inc. has a one year low of $1.27 and a one year high of $3.56. The firm has a market capitalization of $92.13 million, a P/E ratio of -1.14 and a beta of 1.85. The company's fifty day moving average is $1.81 and its two-hundred day moving average is $1.70.
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.07. On average, sell-side analysts forecast that Acrivon Therapeutics, Inc. will post -1.8 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Acrivon Therapeutics
A number of large investors have recently modified their holdings of the stock. UBS Group AG grew its position in Acrivon Therapeutics by 150,057.8% in the third quarter. UBS Group AG now owns 683,218 shares of the company's stock valued at $1,237,000 after acquiring an additional 682,763 shares in the last quarter. Marshall Wace LLP increased its holdings in Acrivon Therapeutics by 231.4% in the fourth quarter. Marshall Wace LLP now owns 496,081 shares of the company's stock valued at $1,196,000 after buying an additional 346,366 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter valued at approximately $371,000. Two Sigma Investments LP raised its holdings in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock worth $578,000 after purchasing an additional 138,033 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Acrivon Therapeutics by 19.6% during the first quarter. Renaissance Technologies LLC now owns 758,440 shares of the company's stock worth $1,054,000 after acquiring an additional 124,271 shares during the period. Institutional investors and hedge funds own 71.62% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered Acrivon Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Acrivon Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.50.
Read Our Latest Stock Report on Acrivon Therapeutics
About Acrivon Therapeutics
(
Get Free Report)
Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.
The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
